The liver must regenerate fast enough to restore function, or the patient faces organ failure.
For decades, surgeons removing diseased liver tissue have watched patients race against the clock of organ regeneration with no pharmacological ally to call upon. A multi-center trial led by Mayo Clinic and Michigan State University now suggests that tranexamic acid — a humble, widely available drug long used to curb bleeding — may reduce the risk of post-hepatectomy liver failure by two-thirds, overturning longstanding assumptions about how the liver heals itself. The finding matters most for those already most vulnerable: patients whose livers are compromised before the first incision is made.
- Post-hepatectomy liver failure kills patients who survive the operating table, and until now no approved drug existed to prevent it — making every high-risk liver resection a wager with narrow odds.
- The discovery upends decades of scientific consensus: researchers once believed plasminogen was essential to liver regeneration, but the trial data shows the opposite — reducing its activity appears to help the liver recover faster.
- Tranexamic acid's mechanism, already trusted in trauma wards and delivery rooms to stabilize clots, turns out to quietly support liver tissue regeneration through the same fibrinolytic pathway it was always known to modulate.
- The protective effect was sharpest in the patients who needed it most — those with pre-existing liver disease — suggesting the drug could redefine surgical preparation for the highest-risk cases.
- Researchers stop short of declaring victory, calling instead for dedicated clinical trials to confirm findings before tranexamic acid is adopted as standard preventive care — but the momentum toward that next step feels difficult to slow.
Surgeons have long understood that removing part of the liver forces the remaining tissue into a desperate race: regenerate fast enough, or the patient faces organ failure — one of the deadliest outcomes that can follow liver resection. For decades, no medication existed to improve those odds. A multi-center trial led by Mayo Clinic and Michigan State University, published in Blood, now suggests that a cheap and widely available drug might change that.
Patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than those who received a placebo. The benefit was most pronounced in patients whose livers were already compromised before surgery — precisely the group at greatest risk. The finding doesn't just offer a potential lifeline; it overturns what the field thought it knew about liver healing.
Transexamic acid has been used for years to prevent excessive bleeding in trauma, childbirth, and dental procedures. It works by stabilizing blood clots, preventing the body's fibrinolytic system from dismantling them too aggressively. What researchers discovered is that this same mechanism appears to support liver regeneration after tissue loss. Earlier scientific models had suggested that plasminogen — a protein central to clot breakdown — was necessary for the liver to heal. By temporarily modulating rather than eliminating that system, the Mayo-led team found the opposite: reduced plasminogen activity enhanced regeneration, both in animal models and in clinical data drawn from the large international HeLiX trial.
The implications are considerable. Post-hepatectomy liver failure remains a leading cause of death after liver resection, and no approved preventive drug currently exists. A low-cost intervention reducing that risk by two-thirds would reshape how surgeons approach high-risk patients. The researchers are measured in their conclusions, calling for dedicated trials before tranexamic acid becomes standard care — but for patients facing liver surgery with already-damaged organs, the possibility that an existing, inexpensive drug might tip the balance toward recovery marks a genuine turning point in what surgery can offer.
Surgeons have long known that removing part of the liver to treat cancer or disease forces the remaining tissue into a race against time. The organ must regenerate quickly enough to restore function, or the patient faces organ failure—one of the deadliest complications that can follow liver resection. For decades, there has been no medication to improve those odds. Now a multi-center trial led by Mayo Clinic and Michigan State University suggests that a cheap, widely available drug might change that calculation.
The study, published in Blood, tracked patients undergoing liver surgery who received either tranexamic acid or a placebo. Those who got the drug were three times less likely to develop post-hepatectomy liver failure than those who received the placebo. The protective effect was strongest in patients whose livers were already compromised before surgery—the very group at highest risk of catastrophic failure. The finding is significant not just because it offers a potential lifeline, but because it overturns decades of scientific assumption about how the liver heals.
Transexamic acid is not new. Hospitals have used it for years to prevent excessive bleeding in trauma cases, during childbirth, and in dental work. The drug works by stabilizing blood clots, preventing the body's natural system for breaking them down from working too aggressively. What researchers discovered is that this mechanism—controlling what's called the fibrinolytic system—appears to support the liver's ability to regenerate after tissue loss. The insight came from pre-clinical work showing that temporarily reducing plasminogen, a protein central to clot breakdown, enhanced liver regeneration in animal models. When the team analyzed data from the HeLiX trial, a large international study of liver resection patients, the clinical evidence aligned with the lab findings.
The implications are substantial. Post-hepatectomy liver failure remains a leading cause of death after liver resection, and currently there are no approved drugs designed specifically to prevent it. A low-cost intervention that could reduce that risk by two-thirds would reshape how surgeons prepare high-risk patients for the operating room. Patrick Starlinger, a hepatobiliary surgeon at Mayo Clinic and co-senior author of the study, noted that the possibility of using an existing medication to substantially improve outcomes is compelling precisely because the drug is already available and inexpensive.
But the finding also challenges what the field thought it knew. For decades, researchers believed plasminogen was necessary for liver regeneration, based on earlier pre-clinical models. By using a more precise and reversible approach—one that temporarily modulates the system rather than permanently eliminating it—Starlinger's team found the opposite effect. The liver regenerated better when plasminogen activity was reduced. That contradiction opens new questions about how the body's clotting and fibrinolytic systems interact with organ recovery, and it suggests there may be other therapeutic angles yet to explore.
The researchers are careful not to overstate what they have found. They call for dedicated clinical trials to confirm the results and determine whether tranexamic acid should become standard preventive care for patients at highest risk. But the evidence is strong enough that the next phase of investigation seems inevitable. For patients facing liver surgery—particularly those with pre-existing liver disease—the possibility that a simple, existing drug might tip the balance between recovery and failure represents a meaningful shift in what surgery can offer.
Notable Quotes
For decades, the field believed plasminogen was necessary for liver regeneration. By using a more precise and reversible approach, we found the opposite effect.— Patrick Starlinger, M.D., Ph.D., hepatobiliary surgeon at Mayo Clinic
The possibility that a widely available, low-cost medication could substantially reduce this risk is exciting because it has the potential to improve outcomes for patients undergoing surgery for liver cancer and other serious liver diseases.— Patrick Starlinger, M.D., Ph.D.
The Hearth Conversation Another angle on the story
Why does the liver struggle to regenerate after surgery when it's normally so good at healing itself?
The organ has to do it under pressure. When you remove tissue, the remaining liver doesn't just need to grow—it needs to grow fast enough to restore function before the patient's body runs into trouble. Some livers can't keep pace, especially if they were already weakened by disease.
And tranexamic acid helps by doing what, exactly?
It slows down the body's natural process of breaking down blood clots. That sounds counterintuitive—you'd think you'd want clots to dissolve. But the research suggests that when you dial back that breakdown process, the liver actually regenerates more efficiently. It's the opposite of what doctors assumed for decades.
So this drug has been around for years, used for bleeding problems, and nobody thought to test it in liver surgery?
Not until someone noticed the connection in the lab. Pre-clinical models showed that reducing a specific clotting protein enhanced regeneration. Once they saw that signal, they looked at the clinical data and found it held up. Sometimes the answer was already in the medicine cabinet.
Who benefits most from this?
Patients whose livers were already damaged before surgery—cirrhosis, fibrosis, advanced disease. They're the ones at highest risk of failure, and they're also the ones who saw the strongest protection from the drug. For them, this could be the difference between recovery and death.
What happens next?
More trials. The researchers want to confirm these findings in a dedicated study and figure out exactly which patients should get it and when. But the evidence is strong enough that it's hard to imagine surgeons won't start thinking about this for their highest-risk cases.